MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. Show more

444 West Lake Street, Chicago, IL, 60606, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

79.99M

52 Wk Range

$0.87 - $3.19

Previous Close

$2.16

Open

$2.15

Volume

2,031,612

Day Range

$1.93 - $2.46

Enterprise Value

49.24M

Cash

10.89M

Avg Qtr Burn

-3.487M

Insider Ownership

19.81%

Institutional Own.

6.80%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ateganosine (THIO; 6-thio-2'-deoxyguanosine) Details Non-small cell lung carcinoma (NSCLC 3L)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ateganosine (THIO; 6-thio-2'-deoxyguanosine) Details Non-small cell lung carcinoma (NSCLC 2L+)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.